Effect of levothyroxine administration on hemostatic analytes in Doberman Pinschers with von Willebrand disease

Journal of Veterinary Internal Medicine

Volumn 19, Issue 4, 2005, Pages 523-527

  Heseltine, Johanna C ^a   Panciera, David L ^b   Troy, Gregory C ^b   Monroe, William E ^b   Brooks, Marjory B ^c   Feldman, Bernard F ^b  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^c Department of Molecular Biology and Genetics   (United States)

Author keywords

Canine; Thyroid; Von Willebrand factor

Indexed keywords

LIOTHYRONINE; THYROTROPIN; THYROXINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOG; DOG DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEMOSTASIS; MALE; RANDOMIZED CONTROLLED TRIAL; VON WILLEBRAND DISEASE;

ANIMALS; CROSS-OVER STUDIES; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; FEMALE; HEMOSTASIS; MALE; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE; VON WILLEBRAND DISEASE;

CANIS FAMILIARIS;

EID: 23744458896     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2005)19[523:EOLAOH]2.0.CO;2     Document Type: Article

References (28)

1. Sadler JE, Matsushita T, Dong Z, et al. Molecular mechanism and classification of von Willebrand disease. Thromb Haemost 1995;74:161-166.
2. Johnson GS, Turrentine MA, Kraus KH. Canine von Willebrand's disease. A heterogeneous group of bleeding disorders. Vet Clin North Am Small Anim Pract 1988;18:195-229.
3. Brooks M. Management of canine von Willebrand's disease. Probl Vet Med 1992;4:636-646.
4. de Gopegui RR, Feldman BF. von Willebrand's disease. Comp Haematol Int 1997;7:187-196.
5. Brooks M. A review of canine inherited bleeding disorders: Biochemical and molecular strategies for disease characterization and carrier detection. J Hered 1999;90:112-118.
6. Dodds WJ. Von Willebrand's disease in dogs. Mod Vet Pract 1984;65:681-686.
7. Brassard JA, Meyers KM. Evaluation of the buccal bleeding time and platelet glass bead retention as assays of hemostasis in the dog: The effects of acetylsalicylic acid, warfarin and von Willebrand factor deficiency. Thromb Haemost 1991;65:191-195.
8. Sato I, Parry BW. Effect of desmopressin on plasma factor VIII and von Willebrand factor concentrations in Greyhounds. Aust Vet J 1998;76:809-812.
9. Jergens AE, Turrentine MA, Kraus KH, et al. Buccal mucosa bleeding times of healthy dogs and of dogs in various pathologic states, including thrombocytopenia, uremia, and von Willebrand's disease. Am J Vet Res 1987;48:1337-1342.
10. Johnstone IB. Plasma von Willebrand factor-collagen binding activity in normal dogs and in dogs with von Willebrand's disease. J Vet Diagn Invest 1999;11:308-313.
11. Favaloro EJ. Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: A 15-year journey. Semin Thromb Hemost 2002;28:191-202.
12. Johnson GS, Schlink GT, Fallon RK, et al. Hemorrhage from the cosmetic otoplasty of Doberman Pinschers with von Willebrand's disease. Am J Vet Res 1985;46:1335-1340.
13. Johnstone IB, Crane S. The effects of desmopressin on plasma factor VIII/von Willebrand factor activity in dogs with von Willebrand's disease. Can J Vet Res 1987;51:189-193.
14. Stokol T, Trepanier L, Parry BW, et al. Pharmacokinetics of von Willebrand factor and factor VIII in canine von Willebrand disease and haemophilia A. Res Vet Sci 1997;63:23-27.
15. Applewhite AA, Wilkens BE, McDonald DE, et al. Potential central nervous system complications of von Willebrand's disease. J Am Anim Hosp Assoc 1999;35:423-429.
16. Avgeris S, Lothrop CD Jr, McDonald TP. Plasma von Willebrand factor concentration and thyroid function in dogs. J Am Vet Med Assoc 1990;196:921-924.
17. Panciera DL, Johnson GS. Plasma von Willebrand factor antigen concentration in dogs with hypothyroidism. J Am Vet Med Assoc 1994;205:1550-1553.
18. Panciera DL, Johnson GS. Plasma von Willebrand factor antigen concentration and buccal mucosal bleeding time in dogs with experimental hypothyroidism. J Vet Intern Med 1996;10:60-64.
19. Benson RE, Catalfamo JL, Brooks M, et al. A sensitive immunoassay for von Willebrand factor. J Immunoassay 1991;12:371-390.
20. Stokol T, Brooks MB, Erb HN. Effect of citrate concentration on coagulation test results in dogs. J Am Vet Med Assoc 2000;217:1672-1677.
21. Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): Detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000;83:127-135.
22. Panciera DL, Post K. Effect of oral administration of sulfadiazine and trimethoprim in combination on thyroid function in dogs. Can J Vet Res 1992;56:349-352.
23. Sauve F, Paradis M, Refsal KR, et al. Effects of oral administration of meloxicam, carprofen, and a nutraceutical on thyroid function in dogs with osteoarthritis. Can Vet J 2003;44:474-479.
24. Panciera DL, Hinchcliff KW, Olson J, et al. Plasma thyroid hormone concentrations in dogs competing in a long-distance sled dog race. J Vet Intern Med 2003;17:593-596.
25. Hofbauer LC, Heufelder AE. Coagulation disorders in thyroid diseases. Eur J Endocrinol 1997;136:1-7.
26. Burstein SA. Effects of interleukin 6 on megakaryocytes and on canine platelet function. Stem Cells 1994;12:386-393.
27. Burggraaf J, Lalezari S, Emeis JJ, et al. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid 2001;11:153-160.
28. Dodds WJ, Raymond SL, Brooks MB. Inherited and acquired von Willebrand's disease. Vet Pract Staff 1993;5:21-23.